| Arsenic trioxide as a treatment for myelodysplastic syndrome. | |
| | |
MedLine Citation:
|
PMID: 20425329 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Myelodysplastic syndrome (MDS) is a heterogeneous bone marrow disorder primarily affecting older adults, for whom the only curative therapy, bone marrow transplantation, is rarely an option. New therapies, or novel applications of historical therapies, are desperately needed. Arsenic trioxide (ATO), which acts through proapoptotic, antiproliferative, and antiangiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. As monotherapy or in combination with other agents, it can effect hematologic improvement in 22% to 26% of patients, with tolerable side effects. MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy. |
| | |
Authors:
|
Mikkael A Sekeres |
Related Documents
:
|
18603319 - Electrolytically detachable coils for closure of a modified baffle fenestration in pati... 6131629 - Klinefelter's and takayasu's syndromes in one patient--a pure coincidence? 6523449 - Plasma fibronectin concentration in patients with acquired consumptive coagulopathies. 3560119 - Retinitis pigmentosa and deafness. 1082749 - Cryoimmunoglobulinemia in felty's syndrome. 7503839 - Strabismus in williams syndrome. 20813859 - Modified c-reactive protein might be a target autoantigen of tinu syndrome. 11442909 - Atrial septal aneurysm and dilated sinus of valsalva in a patient with wolff-parkinson-... 11202479 - Common variable immunodeficiency. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current hematologic malignancy reports Volume: 1 ISSN: 1558-822X ISO Abbreviation: Curr Hematol Malig Rep Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2010-04-28 Completed Date: 2010-07-28 Revised Date: 2010-09-15 |
Medline Journal Info:
|
Nlm Unique ID: 101262565 Medline TA: Curr Hematol Malig Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 34-8 Citation Subset: IM |
Affiliation:
|
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. sekerem@ccf.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
administration & dosage,
therapeutic use Antineoplastic Agents / therapeutic use Apoptosis / drug effects Arsenicals / administration & dosage, pharmacology, therapeutic use* Clinical Trials as Topic DNA-Binding Proteins / genetics Drug Therapy, Combination Humans Leukemia, Promyelocytic, Acute / drug therapy Multicenter Studies as Topic Myelodysplastic Syndromes / drug therapy*, genetics Oxides / administration & dosage, pharmacology, therapeutic use* Proto-Oncogenes / genetics Salvage Therapy Thalidomide / administration & dosage, therapeutic use Transcription Factors / genetics |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents; 0/Arsenicals; 0/DNA-Binding Proteins; 0/MECOM protein, human; 0/Oxides; 0/Transcription Factors; 1327-53-3/arsenic trioxide; 50-35-1/Thalidomide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New agents in myelodysplastic syndromes.
Next Document: Advances in the treatment of chronic lymphocytic leukemia.